Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.

Literature DB >> 24972774

Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.

Catharina Müller-Thomas¹, Martina Rudelius², Ina-Christine Rondak³, Torsten Haferlach⁴, Julie Schanz⁵, Christina Huberle¹, Burkhard Schmidt⁶, Rainer Blaser³, Marcus Kremer⁷, Christian Peschel⁸, Ulrich Germing⁹, Uwe Platzbecker¹⁰, Katharina Götze¹¹.

Abstract

Entities: Chemical Disease Gene

Keywords: MDS; TP53 mutations; azacitidine; p53 expression

Mesh：

Substances：

Year: 2014 PMID： 24972774 PMCID： PMC4181264 DOI： 10.3324/haematol.2014.104760

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

15 in total

1. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

Authors: Martin Jädersten; Leonie Saft; Alexander Smith; Austin Kulasekararaj; Sabine Pomplun; Gudrun Göhring; Anette Hedlund; Robert Hast; Brigitte Schlegelberger; Anna Porwit; Eva Hellström-Lindberg; Ghulam J Mufti
Journal: J Clin Oncol Date: 2011-04-25 Impact factor: 44.544

2. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

Authors: Leonie Saft; Mohsen Karimi; Mehran Ghaderi; András Matolcsy; Ghulam J Mufti; Austin Kulasekararaj; Gudrun Göhring; Aristoteles Giagounidis; Dominik Selleslag; Petra Muus; Guillermo Sanz; Moshe Mittelman; David Bowen; Anna Porwit; Tommy Fu; Jay Backstrom; Pierre Fenaux; Kyle J MacBeth; Eva Hellström-Lindberg
Journal: Haematologica Date: 2014-03-28 Impact factor: 9.941

3. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.

Authors: Felicitas Thol; Inna Friesen; Frederik Damm; Haiyang Yun; Eva M Weissinger; Jürgen Krauter; Katharina Wagner; Anuhar Chaturvedi; Amit Sharma; Martin Wichmann; Gudrun Göhring; Christiane Schumann; Gesine Bug; Oliver Ottmann; Wolf-Karsten Hofmann; Brigitte Schlegelberger; Michael Heuser; Arnold Ganser
Journal: J Clin Oncol Date: 2011-05-16 Impact factor: 44.544

4. Clinical effect of point mutations in myelodysplastic syndromes.

Authors: Rafael Bejar; Kristen Stevenson; Omar Abdel-Wahab; Naomi Galili; Björn Nilsson; Guillermo Garcia-Manero; Hagop Kantarjian; Azra Raza; Ross L Levine; Donna Neuberg; Benjamin L Ebert
Journal: N Engl J Med Date: 2011-06-30 Impact factor: 91.245

5. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.

Authors: Audrey Petitjean; Ewy Mathe; Shunsuke Kato; Chikashi Ishioka; Sean V Tavtigian; Pierre Hainaut; Magali Olivier
Journal: Hum Mutat Date: 2007-06 Impact factor: 4.878

6. International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome.

Authors: Y Kita-Sasai; S Horiike; S Misawa; H Kaneko; M Kobayashi; M Nakao; H Nakagawa; H Fujii; M Taniwaki
Journal: Br J Haematol Date: 2001-11 Impact factor: 6.998

7. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors: Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal: Lancet Oncol Date: 2009-02-21 Impact factor: 41.316

8. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype.

Authors: Dimitri A Breems; Wim L J Van Putten; Georgine E De Greef; Shama L Van Zelderen-Bhola; Klasien B J Gerssen-Schoorl; Clemens H M Mellink; Aggie Nieuwint; Martine Jotterand; Anne Hagemeijer; H Berna Beverloo; Bob Löwenberg
Journal: J Clin Oncol Date: 2008-08-11 Impact factor: 44.544

9. Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis: differential diagnosis between refractory anemia and aplastic anemia.

Authors: Takashi Iwasaki; Masashi Murakami; Chiho Sugisaki; Sayaka Sobue; Haruhiko Ohashi; Haruhiko Asano; Motoshi Suzuki; Shigeo Nakamura; Masafumi Ito; Takashi Murate
Journal: Pathol Int Date: 2008-06 Impact factor: 2.534

10. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.

Authors: Julie Schanz; Heinz Tüchler; Francesc Solé; Mar Mallo; Elisa Luño; José Cervera; Isabel Granada; Barbara Hildebrandt; Marilyn L Slovak; Kazuma Ohyashiki; Christian Steidl; Christa Fonatsch; Michael Pfeilstöcker; Thomas Nösslinger; Peter Valent; Aristoteles Giagounidis; Carlo Aul; Michael Lübbert; Reinhard Stauder; Otto Krieger; Guillermo Garcia-Manero; Stefan Faderl; Sherry Pierce; Michelle M Le Beau; John M Bennett; Peter Greenberg; Ulrich Germing; Detlef Haase
Journal: J Clin Oncol Date: 2012-02-13 Impact factor: 44.544

18 in total

1. Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients.

Authors: S Jilg; V Reidel; C Müller-Thomas; J König; J Schauwecker; U Höckendorf; C Huberle; O Gorka; B Schmidt; R Burgkart; J Ruland; H-J Kolb; C Peschel; R A J Oostendorp; K S Götze; P J Jost
Journal: Leukemia Date: 2015-07-08 Impact factor: 11.528

2. Methylxanthines Increase Expression of the Splicing Factor SRSF2 by Regulating Multiple Post-transcriptional Mechanisms.

Authors: Jia Shi; Kirk Pabon; Kathleen W Scotto
Journal: J Biol Chem Date: 2015-03-28 Impact factor: 5.157

Review 3. Preparing Patients With Myelodysplastic Syndrome for Transplant When Is Pre-transplant Cytoreductive Therapy Appropriate?

Authors: Martin Wermke; Silke Gloaguen; Uwe Platzbecker
Journal: Curr Hematol Malig Rep Date: 2015-09 Impact factor: 3.952

4. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.

Authors: Courtney D DiNardo; Naval Daver; Elias Jabbour; Tapan Kadia; Gautam Borthakur; Marina Konopleva; Naveen Pemmaraju; Hui Yang; Sherry Pierce; William Wierda; Carlos Bueso-Ramos; Keyur P Patel; Jorge E Cortes; Farhad Ravandi; Hagop M Kantarjian; Guillermo Garcia-Manero
Journal: Lancet Haematol Date: 2014-12-22 Impact factor: 18.959

10. CTNNA1 hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome.

Authors: Mianyang Li; Li Gao; Zhenling Li; Junzhong Sun; Hui Zhang; Haoqing Duan; Yigai Ma; Chengbin Wang
Journal: Oncotarget Date: 2016-05-24